Reassuring evidence on infection risk with dupilumab in atopic dermatitis: Lessons from real‐world evidence
Open Access
- 24 November 2025
- journal article
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 39 (12) , 2026-2027
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- The real‐world, long‐term risk of infections associated with dupilumab in atopic dermatitis: A global cohort studyJournal of the European Academy of Dermatology and Venereology, 2025
- Infection risk in atopic dermatitis patients treated with biologics and JAK inhibitors: BioDay resultsJournal of the European Academy of Dermatology and Venereology, 2025
- Comparative safety of oral Janus kinase inhibitors versus dupilumab in patients with atopic dermatitis: A population-based cohort studyJournal of Allergy and Clinical Immunology, 2024
- Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trialsJournal of Allergy and Clinical Immunology, 2023
- Comorbidities of atopic dermatitis—what does the evidence say?Journal of Allergy and Clinical Immunology, 2023